199 related articles for article (PubMed ID: 21888295)
1. [Fabry-Anderson disease: current state of knowledge].
Vega-Vega O; Pérez-Gutiérrez A; Correa-Rotter R
Rev Invest Clin; 2011; 63(3):314-21. PubMed ID: 21888295
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
3. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
Barbey F; Widmer U; Burnier M; Lidove O
Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
[TBL] [Abstract][Full Text] [Related]
4. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
5. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
6. Anderson-Fabry disease and the heart.
O'Mahony C; Elliott P
Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
[TBL] [Abstract][Full Text] [Related]
7. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
[TBL] [Abstract][Full Text] [Related]
8. [Neurological complications of Fabry-disease].
Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
[TBL] [Abstract][Full Text] [Related]
9. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
10. A novel small insertion mutation, C.1030_1031ins (T) in α-galactosidase A leads to renal variant fabry disease.
Choi JS; Kim CS; Park JW; Bae EH; Ma SK; Choi YD; Kim GH; Yoo HW; Kim SW
Ren Fail; 2012; 34(3):390-3. PubMed ID: 22260214
[TBL] [Abstract][Full Text] [Related]
11. [alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)].
Okumiya T; Takata T; Sasaki M; Sakuraba H
Rinsho Byori; 1997 Feb; 45(2):127-35. PubMed ID: 9120996
[TBL] [Abstract][Full Text] [Related]
12. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
Desnick RJ; Banikazemi M
Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
[TBL] [Abstract][Full Text] [Related]
14. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
Germain DP
J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
[TBL] [Abstract][Full Text] [Related]
15. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease.
Germain DP
Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
[TBL] [Abstract][Full Text] [Related]
17. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.
Garman SC; Garboczi DN
J Mol Biol; 2004 Mar; 337(2):319-35. PubMed ID: 15003450
[TBL] [Abstract][Full Text] [Related]
18. [Fabry disease in Italy: first epidemiologic and collaborative study].
Ricci R; Castorina M; Di Lillo M; Antuzzi D; Frustaci A; Parini R; Menni F; Furlan F; Burlina A; Burlina A; Catuogno S; Gabrielli O; Burattini I; Borsini W; Buchner S; Ferriozzi S; Spisni C; De Vito R; Di Rocco M; Aricò M; Pistone G; Bongiorno AM; Morrone A; Cavicchi C; Zammarchi E
Ann Ital Med Int; 2004; 19(4):269-75. PubMed ID: 15678707
[TBL] [Abstract][Full Text] [Related]
19. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
20. [Alpha-galactosidases and alpha-N-acetylgalactosaminidase. Biochemical bases of Fabry's disease].
Salvayre R; Negre A; Maret A; Douste-Blazy L
Pathol Biol (Paris); 1984 Apr; 32(4):269-84. PubMed ID: 6326022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
